Elon Musk, in a teleconference with Neuralink executives, announced that the company’s brain implant might be placed in a second patient soon, following the February implantation in a 29-year-old quadriplegic.

Initially, the implantation was declared entirely successful, with the patient shown operating a computer using mental commands. However, it was later revealed that a serious complication occurred during the surgery, which appears to have been overcome. Neuralink has stated that it is making adjustments to address the issues faced with its first patient.

Neuralink has developed a brain-computer interface (BCI). The first model, named Telepathy, includes 64 "threads" inserted directly into the brain. These threads, thinner than a human hair, record neural signals via 1,024 electrodes.

BCI systems have been researched for decades, but only in the past 3-4 years have they begun to achieve functional versions tested on humans. Various companies, such as Synchron, Paradromics, and Precision Neuroscience, have conducted human trials before Neuralink. However, with Elon Musk as its owner, Neuralink has unsurprisingly dominated publicity in this rapidly growing tech industry sector. Notably, no BCI company has received approval from the U.S. Food and Drug Administration for the commercial release of their devices.